A Humanized Immunoenzyme with Enhanced Activity for Glucuronide Prodrug Activation in the Tumor Microenvironment

详细信息    查看全文

• 作者：Kai-Chuan Chen ; Shih-Yen Wu ; Yu-Lin Leu ; Zeljko M. Prijovich ; Bing-Mae Chen ; Hsin-Ell Wang ; Tian-Lu Cheng ; Steve R. Roffler
• 刊名：Bioconjugate Chemistry
• 出版年：2011
• 出版时间：May 18, 2011
• 年：2011
• 卷：22
• 期：5
• 页码：938-948
• 全文大小：1080K
• 年卷期：v.22,no.5(May 18, 2011)
• ISSN：1520-4812

文摘

Antibody-directed enzyme prodrug therapy (ADEPT) utilizing 尾-glucuronidase is a promising method to enhance the therapeutic index of cancer chemotherapy. In this approach, an immunoenzyme (antibody-尾-glucuronidase fusion protein) is employed to selectively activate anticancer glucuronide prodrugs in the tumor microenvironment. A major roadblock to the clinical translation of this therapeutic strategy, however, is the low enzymatic activity and strong immunogenicity of the current generation of immunoenzymes. To overcome this problem, we fused a humanized single-chain antibody (scFv) of mAb CC49 to S2, a human 尾-glucuronidase (h尾G) variant that displays enhanced catalytic activity for prodrug hydrolysis. Here, we show that hcc49-S2 displayed 100-fold greater binding avidity than hcc49 scFv, possessed greater enzymatic activity than wild-type h尾G, and more effectively killed antigen-positive cancer cells exposed to an anticancer glucuronide prodrug as compared to an analogous h尾G immunoenzyme. Treatment of tumor-bearing mice with hcc49-S2 followed by prodrug significantly delayed tumor growth as compared to hcc49-h尾G. Our study shows that hcc49-S2 is a promising targeted enzyme for cancer treatment and demonstrates that enhancement of human enzyme catalytic activity is a powerful approach to improve immunoenzyme efficacy.